YARW
Yarrow Bioscience, Inc.Company Information
- Company Name
- Yarrow Bioscience, Inc.
- CIK
- CIK0001566044
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- YARW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- YARW
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-15
- Last sale
- —
- Shares purchased (TTM)
- 15,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 12,975,411
- Shares outstanding
- 858,000
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -29.28%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 23 | 25 | 24 | 22 | 28 | 20 | 16 | 30 | 19 | 31 | 15 | ||||||
| Marketable Securities Current | 0 | 0 | 5 | 18 | 22 | 42 | 54 | 48 | 67 | 63 | - | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 5 | 5 | 3 | 3 | 6 | 4 | 3 | 2 | ||||||
| Assets Current | 24 | 26 | 30 | 44 | 55 | 64 | 74 | 84 | 90 | 96 | 18 | ||||||
Assets Noncurrent | |||||||||||||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Noncurrent | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 | 1 | - | 2 | ||||||
| Prepaid Expense Noncurrent | - | - | - | - | - | 2 | - | - | - | 2 | - | ||||||
| Assets Noncurrent | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 3 | 1 | 2 | - | ||||||
| Assets | 24 | 26 | 30 | 45 | 56 | 67 | 76 | 87 | 92 | 98 | 19 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Trade Current | 1 | 0 | 1 | 1 | 4 | 3 | 4 | 5 | 3 | 2 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 4 | 7 | 9 | 6 | 5 | 4 | 4 | 4 | ||||||
| Employee Related Liabilities Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | ||||||
| Operating Lease Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Supplemental Unemployment Benefits Severance Benefits | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Other Liabilities Current | - | - | 0 | 0 | 1 | 1 | 1 | 1 | - | 0 | - | ||||||
| Liabilities Current | 2 | 1 | 2 | 6 | 12 | 15 | 13 | 12 | 7 | 8 | 6 | ||||||
| Liabilities | 2 | 1 | 2 | 6 | 12 | 15 | 13 | 12 | 8 | 9 | 8 | ||||||
Liabilities Noncurrent | |||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
Temporary Equity | |||||||||||||||||
| Other Liabilities | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | - | - | - | - | - | 0 | 0 | 0 | 1 | 1 | - | ||||||
| Additional Paid In Capital | 786 | 786 | 785 | 784 | 784 | 783 | 783 | 782 | 781 | 780 | 697 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | - | ||||||
| Retained Earnings Accumulated Deficit | -764 | -761 | -758 | -746 | -740 | -731 | -719 | -707 | -698 | -691 | -685 | ||||||
| Stockholders Equity | 22 | 25 | 28 | 39 | 44 | 52 | 64 | 75 | 83 | 89 | 12 | ||||||
| Liabilities And Stockholders Equity | 24 | 26 | 30 | 45 | 56 | 67 | 76 | 87 | 92 | 98 | 19 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | 20 | 20 | ||||||
| Common Stock Shares Authorized | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | ||||||
| Common Stock Shares Issued | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Shares Outstanding | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialYarrow Bioscience, Inc. (YARW) — SEC Financial Statements & Analysis
Yarrow Bioscience, Inc. (YARW) is a pharmaceutical preparations company, incorporated in DE. Yarrow Bioscience, Inc. trades on Nasdaq as: YARW. Yarrow Bioscience, Inc. (YARW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Yarrow Bioscience, Inc. carries a market cap of $15.76M, a P/E ratio of -1.28x, a P/B ratio of 0.71x, a P/S ratio of 62.56x, an enterprise value of $-7.16M, and an EV/EBITDA multiple of 0.50x. On profitability, it posts an operating margin of -5738.10%, a net margin of -4899.60%, a Return on Equity (ROE) of -37.31%, a Return on Assets (ROA) of -30.86%, and a Return on Invested Capital (ROIC) of -127.74%. Per share, it reports EPS of $-14.39, diluted EPS of $-14.39, free cash flow per share of $-19.67, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -58.35% year-over-year, net income growth of -70.74% year-over-year, and EPS growth of -70.89% year-over-year. On the balance sheet, it maintains a current ratio of 15.26x, a quick ratio of 14.87x, working capital of $21.98M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.07, free cash flow of $-16.88M (TTM), and net debt of $-22.93M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.76M
- P/E TTM
- -1.28x
- EPS TTM
- $-14.39
- P/B TTM
- 0.71x
- ROE TTM
- -37.31%
- ROA TTM
- -30.86%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-16.88M
- Net Revenue TTM Growth 1Y
- -58.35%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Yarrow Bioscience, Inc. in?
Yarrow Bioscience, Inc. (YARW) operates in the Pharmaceutical Preparations industry.
What exchange does YARW trade on?
Yarrow Bioscience, Inc. (YARW) trades on the Nasdaq.
Where is Yarrow Bioscience, Inc. incorporated?
Yarrow Bioscience, Inc. is incorporated in DE.
When was Yarrow Bioscience, Inc. (YARW)'s most recent SEC filing?
Yarrow Bioscience, Inc. (YARW)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is YARW's market cap?
Yarrow Bioscience, Inc. (YARW) has a market capitalization of $15.76M as of 2026-06-30.
What is YARW's EPS (earnings per share)?
Yarrow Bioscience, Inc. (YARW)'s trailing twelve month EPS is $-14.39 as of 2026-06-30.
What is YARW's ROE (return on equity)?
Yarrow Bioscience, Inc. (YARW)'s trailing twelve month Return on Equity (ROE) is -37.31% as of 2026-06-30.
What is YARW's ROA (return on assets)?
Yarrow Bioscience, Inc. (YARW)'s trailing twelve month Return on Assets (ROA) is -30.86% as of 2026-06-30.
What is YARW's ROIC (return on invested capital)?
Yarrow Bioscience, Inc. (YARW)'s trailing twelve month Return on Invested Capital (ROIC) is -127.74% as of 2026-03-31.
What is YARW's EV/EBITDA?
Yarrow Bioscience, Inc. (YARW)'s trailing twelve month EV/EBITDA is 0.50x as of 2026-06-30.